IONIS PHARMACEUTICALS INC
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Index
| PART I · FINANCIAL INFORMATION | ||
|---|---|---|
| ITEM 1: · Financial Statements: | ||
| Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and December 31, 2025 | 3 | |
| Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 (unaudited) | 4 | |
| Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2026 and 2025 (unaudited) | 5 | |
| Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2026 and 2025 (unaudited) | 6 | |
| Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 (unaudited) | 8 | |
| Notes to Condensed Consolidated Financial Statements (unaudited) | 9 | |
| ITEM 2: | Management’s Discussion and Analysis of Financial Condition and Results of Operations: | |
| Overview | 28 | |
| Critical Accounting Estimates | 30 | |
| Results of Operations | 31 | |
| Liquidity and Capital Resources | 37 | |
| ITEM 3: | Quantitative and Qualitative Disclosures about Market Risk | 39 |
| ITEM 4: | Controls and Procedures | 39 |
| PART II | OTHER INFORMATION | 40 |
| ITEM 1: | Legal Proceedings | 40 |
| ITEM 1A: | Risk Factors | 40 |
| ITEM 2: | Unregistered Sales of Equity Securities and Use of Proceeds | 58 |
| ITEM 3: | Default upon Senior Securities | 58 |
| ITEM 4: | Mine Safety Disclosures | 58 |
| ITEM 5: | Other Information | 58 |
| ITEM 6: | Exhibits | 59 |
| SIGNATURES | 60 | |
TRADEMARKS
“Ionis,” the Ionis logo, and other trademarks or service marks of Ionis Pharmaceuticals, Inc. appearing in this report are the property of Ionis Pharmaceuticals, Inc. “Akcea,” the Akcea logo, and other trademarks or service marks of Akcea Therapeutics, Inc. appearing in this report are the property of Akcea Therapeutics, Inc., Ionis’ wholly owned subsidiary. This report contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this report may appear without the ® or TM symbols.
Index
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.